ORCA-1

Design

  • Placebo-controlled & double-blind
  • 3 treatment arms: Placebo vs 6 or 12 weeks cytisinicline
  • Cytisinicline treatment for 6 or 12 weeks

    • Does longer treatment lead to better efficacy?
    • Does continued treatment prevent early relapses?
  • Primary Endpoint: 4-week continuous abstinence ON treatment
  • Follow up to 6 months
Laburnum anagyroides plant
ORCA-2 Schematic

ORCA-2 Trial Locations

ORCA-2 is being conducted at the following locations in the US.

AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY DC

Atlanta Clinical Research

The General Hospital Coporation
d/b/a Massachusetts General Hospital

FutureSearch Trials of Dallas

MediSphere Medical Research Center, LLC

Alliance for Multispecialty Research (CPR)

Alliance for Multispecialty Research
(Volunteer Research Group)

Alliance for Multispecialty Research
(AMR Las Vegas)
Alliance for Multispecialty Research
(Central Kentucky Research)
Alliance for Multispecialty Research
(Clinical Research of South Florida)
Alliance for Multispecialty Research
(Coastal Clinical Research)

Coastal Carolina Research

Alliance for Multispecialty Research
(New Orleans Center for Clinical Research)

Alliance for Multispecialty Research
(Tidewater Clinical Research Associates)

Arizona State University

M3 Wake Research, Inc.

Rochester Clinical Research

Alliance for Multispecialty Research
(Heartland Research)